Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.

Steinheimer S, Dorn JF, Morrison C, Sarkar A, D'Souza M, Boisvert J, Bedi R, Burggraaff J, Kontschieder P, Dahlke F, Sellen A, Uitdehaag BMJ, Kappos L, Kamm CP.

Disabil Rehabil. 2019 Feb 20:1-7. doi: 10.1080/09638288.2018.1563832. [Epub ahead of print]

PMID:
30782055
2.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

3.

Northern cod species face spawning habitat losses if global warming exceeds 1.5°C.

Dahlke FT, Butzin M, Nahrgang J, Puvanendran V, Mortensen A, Pörtner HO, Storch D.

Sci Adv. 2018 Nov 28;4(11):eaas8821. doi: 10.1126/sciadv.aas8821. eCollection 2018 Nov.

4.

Impact of Ocean Acidification and Warming on the bioenergetics of developing eggs of Atlantic herring Clupea harengus.

Leo E, Dahlke FT, Storch D, Pörtner HO, Mark FC.

Conserv Physiol. 2018 Sep 18;6(1):coy050. doi: 10.1093/conphys/coy050. eCollection 2018.

5.

Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM.

Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690. [Epub ahead of print]

6.

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.

D'Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, Burggraaff J, van Munster CE, Diederich M, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, Kappos L.

Mult Scler J Exp Transl Clin. 2018 Aug 9;4(3):2055217318792399. doi: 10.1177/2055217318792399. eCollection 2018 Jul-Sep.

7.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
8.

Forecasting future recruitment success for Atlantic cod in the warming and acidifying Barents Sea.

Koenigstein S, Dahlke FT, Stiasny MH, Storch D, Clemmesen C, Pörtner HO.

Glob Chang Biol. 2018 Jan;24(1):526-535. doi: 10.1111/gcb.13848. Epub 2017 Sep 1.

PMID:
28755499
9.

Corrigendum to "Early life stages of an arctic keystone species (Boreogadus saida) show high sensitivity to a water-soluble fraction of crude oil" [Environ. Pollut. 218 (November) (2016) 605-614].

Nahrgang J, Dubourg P, Frantzen M, Storch D, Dahlke F, Meador JP.

Environ Pollut. 2017 Apr;223:120. doi: 10.1016/j.envpol.2016.12.062. Epub 2017 Jan 20. No abstract available.

PMID:
28117185
10.

Effects of ocean acidification increase embryonic sensitivity to thermal extremes in Atlantic cod, Gadus morhua.

Dahlke FT, Leo E, Mark FC, Pörtner HO, Bickmeyer U, Frickenhaus S, Storch D.

Glob Chang Biol. 2017 Apr;23(4):1499-1510. doi: 10.1111/gcb.13527. Epub 2016 Nov 1.

PMID:
27718513
11.

Early life stages of an arctic keystone species (Boreogadus saida) show high sensitivity to a water-soluble fraction of crude oil.

Nahrgang J, Dubourg P, Frantzen M, Storch D, Dahlke F, Meador JP.

Environ Pollut. 2016 Nov;218:605-614. doi: 10.1016/j.envpol.2016.07.044. Epub 2016 Aug 6. Erratum in: Environ Pollut. 2017 Apr;223:120.

12.

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.

D'Souza M, Yaldizli Ö, John R, Vogt DR, Papadopoulou A, Lucassen E, Menegola M, Andelova M, Dahlke F, Schnyder F, Kappos L.

Mult Scler. 2017 Apr;23(4):597-603. doi: 10.1177/1352458516657439. Epub 2016 Jul 11.

PMID:
27364325
13.

Effects of different limestone particle sizes in the diet of broiler breeders post molting on their performance, egg quality, incubation results, and pre-starter performance of their progeny.

Bueno IJ, Surek D, Rocha C, Schramm VG, Muramatsu K, Dahlke F, Maiorka A.

Poult Sci. 2016 Apr;95(4):860-6. doi: 10.3382/ps/pev438. Epub 2016 Jan 14.

PMID:
26769267
14.

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.

Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, Bischof D, Moore A, Simeone J, Fraeman K, Bancken F, Geissbühler Y, Wagner M, Cohan S.

Mult Scler Relat Disord. 2015 Nov;4(6):546-54. doi: 10.1016/j.msard.2015.08.005. Epub 2015 Aug 18.

15.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

16.

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.

Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A, Radue EW, Giovannoni G, Kappos L.

Neurology. 2015 Apr 21;84(16):1639-43. doi: 10.1212/WNL.0000000000001491. Epub 2015 Mar 25.

17.

Vitamin E and selenium in broiler breeder diets: Effect on live performance, hatching process, and chick quality.

Urso UR, Dahlke F, Maiorka A, Bueno IJ, Schneider AF, Surek D, Rocha C.

Poult Sci. 2015 May;94(5):976-83. doi: 10.3382/ps/pev042. Epub 2015 Feb 22.

PMID:
25713394
18.

Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis.

Capkun G, Lahoz R, Verdun E, Song X, Chen W, Korn JR, Dahlke F, Freitas R, Fraeman K, Simeone J, Johnson BH, Nordstrom B.

Curr Med Res Opin. 2015 May;31(5):1029-39. doi: 10.1185/03007995.2015.1014029. Epub 2015 Mar 4.

PMID:
25661016
19.

Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision.

Morrison C, D'Souza M, Huckvale K, Dorn JF, Burggraaff J, Kamm CP, Steinheimer SM, Kontschieder P, Criminisi A, Uitdehaag B, Dahlke F, Kappos L, Sellen A.

JMIR Hum Factors. 2015 Jun 24;2(1):e11. doi: 10.2196/humanfactors.4129.

20.

Quantifying progression of multiple sclerosis via classification of depth videos.

Kontschieder P, Dorn JF, Morrison C, Corish R, Zikic D, Sellen A, D'Souza M, Kamm CP, Burggraaff J, Tewarie P, Vogel T, Azzarito M, Glocker B, Chin P, Dahlke F, Polman C, Kappos L, Uitdehaag B, Criminisi A.

Med Image Comput Comput Assist Interv. 2014;17(Pt 2):429-37.

PMID:
25485408
21.

Relapses in patients treated with fingolimod after previous exposure to natalizumab.

Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P, Tomic D, Kappos L.

Mult Scler. 2015 May;21(6):786-90. doi: 10.1177/1352458514549404. Epub 2014 Sep 25.

PMID:
25257618
22.

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.

Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.

Lancet Neurol. 2013 Aug;12(8):756-67. doi: 10.1016/S1474-4422(13)70102-9. Epub 2013 Jun 11. Erratum in: Lancet Neurol. 2013 Sep;12(9):846.

PMID:
23764350
23.

High- and low-temperature manipulation during late incubation: effects on embryonic development, the hatching process, and metabolism in broilers.

Willemsen H, Kamers B, Dahlke F, Han H, Song Z, Ansari Pirsaraei Z, Tona K, Decuypere E, Everaert N.

Poult Sci. 2010 Dec;89(12):2678-90. doi: 10.3382/ps.2010-00853.

PMID:
21076107
24.

Genomics and proteomics: role in the management of multiple sclerosis.

Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, Lindberg RL.

J Neurol. 2005 Sep;252 Suppl 3:iii21-iii27. Review.

PMID:
16170496
25.

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.

Rieckmann P, Kruse N, Nagelkerken L, Beckmann K, Miller D, Polman C, Dahlke F, Toyka KV, Hartung HP, Stürzebecher S.

J Neurol. 2005 May;252(5):526-33.

PMID:
15895275
26.

Interferon beta-1b treatment does not induce autoantibodies.

Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, Pozzilli C, Thompson AJ; European Study Group on Interferon Beta-1b in SPMS.

Neurology. 2005 Mar 22;64(6):996-1000.

PMID:
15781815
27.

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.

Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board.

Neurology. 2004 Nov 23;63(10):1779-87.

PMID:
15557490
28.

[Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life].

Ganzinger U, Badelt C, Vass K, Strasser-Fuchs S, Fazekas F, Berger T, Dahlke F.

Nervenarzt. 2004 Oct;75(10):1000-6. German.

PMID:
15150646
29.

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group.

Mult Scler. 2003 Aug;9(4):342-8.

PMID:
12926838
30.

Can the Expanded Disability Status Scale be assessed by telephone?

Lechner-Scott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, Tintore M, Frontoni M, Buttinelli C, Amato MP, Bartolozzi ML, Versavel M, Dahlke F, Kapp JF, Gibberd R.

Mult Scler. 2003 Mar;9(2):154-9.

PMID:
12708811
31.

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.

Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D; European Study Group in Interferon Beta-1b in Secondary Progressive MS.

Neurology. 2003 Jan 14;60(1):37-43.

PMID:
12525715
32.

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.

Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C.

J Neurol. 2002 Jan;249(1):50-6.

PMID:
11954868
33.

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; European Study Group on Interferon Beta-1b in Secondary Progressive MS.

Neurology. 2001 Dec 26;57(12):2191-7.

PMID:
11756596
34.

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.

Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F; European Study Group in Interferon beta-1b in Secondary-Progressive MS.

Neurology. 2001 Dec 11;57(11):1969-75.

PMID:
11739811
35.

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C; European Study Group on Interferon-beta1b in Secondary Progressive MS.

Neurology. 2001 Nov 27;57(10):1870-5.

PMID:
11723278
36.

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH.

Brain. 2000 Nov;123 ( Pt 11):2256-63.

PMID:
11050025
37.

Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy.

Claus JJ, de Koning I, van Harskamp F, Breteler MM, Voet B, Gutzmann H, Dahlke F, van der Cammen T, Hofman A.

Clin Neuropharmacol. 1998 May-Jun;21(3):190-5.

PMID:
9617511
38.

Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C.

Mult Scler. 1995;1 Suppl 1:S51-4.

PMID:
9345400
39.

Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research.

Dahlke F, Lohaus A, Gutzmann H.

Psychopharmacol Bull. 1992;28(4):425-32.

PMID:
1296220
40.

Treating chronic hemiparesis with modified biofeedback.

Wissel J, Ebersbach G, Gutjahr L, Dahlke F.

Arch Phys Med Rehabil. 1989 Aug;70(8):612-7.

PMID:
2764691

Supplemental Content

Loading ...
Support Center